Medicare Program; CY 2018 Updates to the Quality Payment Program; and Quality Payment Program: Extreme and Uncontrollable Circumstance Policy for the Transition Year; Corrections, 23584-23610 [2018-10923]
Download as PDF
<![CDATA[
23584
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Medicare & Medicaid
Services
42 CFR Part 414
[CMS–5522–F2]
RIN 0938–AT13
Medicare Program; CY 2018 Updates to
the Quality Payment Program; and
Quality Payment Program: Extreme
and Uncontrollable Circumstance
Policy for the Transition Year;
Corrections
Centers for Medicare &
Medicaid Services (CMS), HHS.
ACTION: Final rule with comment period
and interim final rule with comment
period; correction and correcting
amendment.
AGENCY:
This document corrects
technical errors that appeared in the
final rule with comment period and
interim final rule with comment period
published in the Federal Register on
November 16, 2017 entitled ‘‘Medicare
Program; CY 2018 Updates to the
Quality Payment Program; and Quality
Payment Program: Extreme and
Uncontrollable Circumstance Policy for
the Transition Year’’ (hereinafter
referred to as the ‘‘CY 2018 Quality
Payment Program final rule’’).
DATES: This correction is effective May
22, 2018.
FOR FURTHER INFORMATION CONTACT:
Molly MacHarris, (410) 786–4461, for
inquiries related to MIPS.
Benjamin Chin, (410) 786–0679, for
inquiries related to APMs.
SUPPLEMENTARY INFORMATION:
SUMMARY:
amozie on DSK3GDR082PROD with RULES
I. Background
In FR Doc. 2017–24067 (82 FR 53568),
the final rule with comment period and
interim final rule with comment period
there were a number of technical errors
that are identified and corrected in the
Correction of Errors section of this
correcting document. The provisions in
this correction document are effective as
if they had been included in the
document published in the Federal
Register on November 16, 2017.
Accordingly, the corrections are
applicable for program years beginning
January 1, 2018.
II. Summary of Errors
A. Summary of Errors in Preamble
On page 53577, we inadvertently
made an error in citing the incremental
collection of information-related
burden.
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
On page 53743, we inadvertently
made an error in identifying the
regulation text citation.
On page 53744, we inadvertently
made an error in identifying the
regulation text citation.
On page 53900, we inadvertently
made an error in citing the reduction in
burden cost relative to a baseline of
continuing the policies in the CY 2017
Quality Payment Program final rule.
On page 53911, we inadvertently
made an error in citing the estimated
data submission burden for the Quality
Payment Program.
On page 53925, we inadvertently
made an error in citing the total
estimated labor cost for annual
recordkeeping and data submission.
On page 53925, we inadvertently
made an error in citing the decrease in
labor cost burden relative to the
estimated baseline of continued
transition year policies.
On page 53925, Table 74—Annual
Recordkeeping And Submission
Requirements
a. Sixth column titled ‘‘Total annual
burden cost’’, second row, we
inadvertently made an error in citing the
total annual burden cost for QCDR and
Registries self-nomination.
b. Sixth column titled ‘‘Total annual
burden cost’’, nineteenth row, we
inadvertently made an error in citing the
total annual burden cost.
On page 53927, we inadvertently
made an error in citing the reduction in
burden costs in the Quality Payment
Program Year 2 relative to Quality
Payment Program Year 1.
On page 53950, we inadvertently
made an error in citing the collection of
information-related burden associated
with the CY 2018 Quality Payment
Program final rule with comment
period.
On page 53950, we inadvertently
made an error in citing the reduction in
incremental collection of informationrelated burden associated with the CY
2018 Quality Payment Program final
rule with comment period relative to the
baseline burden of continuing the
policies and information collections set
forth in the CY 2017 Quality Program
final rule.
On page 53950, Table 81—Additional
Costs And Benefits, in the second
column titled ‘‘Costs/benefits’’, second
row, we inadvertently made an error in
citing the incremental collection of
information/Paperwork Reduction Act
burden estimates.
B. Summary of Errors in Regulation Text
On page 53954, in the regulation text
at § 414.1370(g)(1)(ii)(B), we
inadvertently made errors in identifying
PO 00000
Frm 00010
Fmt 4700
Sfmt 4700
the beginning CY performance period
for which CMS calculates a quality
improvement score for an APM Entity.
On page 53954, at
414.1370(h)(5)(i)(B), due to
typographical errors, the percent values
for the advancing care information
performance category and the
improvement activities performance
category are incorrect.
On page 53957, we inadvertently
made an error in identifying the
regulation text citation.
On page 53961, at § 414.1420(d)(3)(i),
we inadvertently deleted the existing
regulation text regarding the expected
expenditures standard.
C. Summary of Errors in Appendix
On page 53969, Table A.3. Average
Change in Leg Pain following Lumbar
Discectomy/Laminotomy, Quality #461,
we inadvertently omitted the MAP
recommendation description in the
‘‘Rationale’’.
On page 53970, Table A.4. Bone
Density Evaluation for Patients with
Prostate Cancer and Receiving
Androgen Deprivation Therapy, Quality
#462, we incorrectly identified the MAP
recommendation description in the
‘‘Rationale’’.
On page 53971, Table A.5. Prevention
of Post-Operative Vomiting (POV)—
Combination Therapy (Pediatrics),
Quality #463 we inadvertently omitted
the MAP recommendation description
in the ‘‘Rationale’’.
On page 53973, Table A.7. Uterine
Artery Embolization Technique:
Documentation of Angiographic
Endpoints and Interrogation of Ovarian
Arteries, Quality #465, we inadvertently
omitted the MAP recommendation
description in the ‘‘Rationale’’.
On page 53976, Table B.1. Allergy/
Immunology in the first column titled
‘‘Indicator’’, third row, we inadvertently
omitted the high priority symbol.
On page 53977, Table B.1. Allergy/
Immunology (continued) in the first
column titled ‘‘Indicator’’, second row,
we inadvertently omitted the high
priority symbol.
On page 53978, Table B.1. Allergy/
Immunology (continued) in the first
column titled ‘‘Indicator’’, third row, we
inadvertently omitted the CORE
measure and the high priority symbols.
On page 53985, Table B.3. Cardiology
(continued) in the first column titled
‘‘Indicator’’,
a. Third row, we inadvertently
omitted the CORE measure and the high
priority symbols.
b. Fourth row, we inadvertently
omitted the high priority symbol.
On page 53986, Table B.3. Cardiology
(continued) in the first column titled
E:\FR\FM\22MYR1.SGM
22MYR1
amozie on DSK3GDR082PROD with RULES
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
‘‘Indicator’’, first row, we inadvertently
omitted the high priority symbol.
On page 53987, Table B.3. Cardiology
(continued) in the first column titled
‘‘Indicator’’, fifth row, we inadvertently
omitted the high priority symbol.
On page 53992, Table B.4.
Gastroenterology (continued) in the first
column titled ‘‘Indicator’’, third row, we
inadvertently omitted the CORE
measure symbol.
On page 53997, Table B.5.
Dermatology (continued),
a. First column titled ‘‘Indicator’’,
third row, we inadvertently omitted the
high priority symbol.
b. Fifth column titled ‘‘Data
Submission Method’’, second row, we
inadvertently listed an incorrect claims
submission method.
On page 54006, Table B.7. Family
Medicine (continued) in the fourth
column titled ‘‘CMS E-measure ID’’,
fifth row, we inadvertently listed an
incorrect E-measure ID.
On page 54007, Table B.7. Family
Medicine (continued) in the first
column titled ‘‘Indicator’’, second row,
we inadvertently omitted the high
priority symbol.
On page 54009, Table B.7. Family
Medicine (continued) in the first
column titled ‘‘Indicator’’, first and
second rows, we inadvertently omitted
the high priority symbol.
On page 54010, Table B.7. Family
Medicine (continued),
a. Second column titled ‘‘NQF#’’,
third row, due to a typographical error,
we included an incorrect NQF#.
b. Ninth column titled ‘‘Measure
Steward’’, third row, we inadvertently
omitted the Centers for Medicare &
Medicaid Services (CMS) as a costeward.
On page 54012, Table B.7. Family
Medicine (continued) in the first
column titled ‘‘Indicator’’, fifth row, we
inadvertently omitted the high priority
symbol.
On page 54013, Table B.7. Family
Medicine (continued) in the first
column titled ‘‘Indicator’’, first row, we
inadvertently omitted the high priority
symbol.
On page 54023, Table B.8. Internal
Medicine (continued), in the first
column titled ‘‘Indicator’’, First and
second rows, we inadvertently omitted
the high priority symbol.
On pages 54024, Table B.8. Internal
Medicine (continued),
a. Second column titled ‘‘NQF#’’,
third row, due to a typographical error,
we included an incorrect NQF#.
b. Ninth column titled ‘‘Measure
Steward’’, third row, we inadvertently
omitted the Centers for Medicare &
Medicaid Services (CMS) as a costeward.
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
On page 54027, Table B.8. Internal
Medicine (continued), in the first
column titled ‘‘Indicator’’, third and
fifth rows, we inadvertently omitted the
high priority symbol.
On page 54036, Table B.9. Obstetrics/
Gynecology (continued), in the first
column titled ‘‘Indicator’’, sixth row, we
inadvertently omitted the high priority
symbol.
On page 54037, Table B.9. Obstetrics/
Gynecology (continued), in the first
column titled ‘‘Indicator’’, second and
fourth rows, we inadvertently omitted
the high priority symbol.
On page 54038, Table B.9. Obstetrics/
Gynecology (continued), ninth column,
fourth row, we inadvertently listed an
incorrect measure steward.
On page 54047, Table B.11.
Orthopedic Surgery (continued) in the
first column titled ‘‘Indicator’’, fifth
row, we inadvertently omitted the high
priority symbol.
On page 54049, Table B.11.
Orthopedic Surgery (continued) in the
first column titled ‘‘Indicator’’, third
row, we inadvertently omitted the
substantive change symbol.
On page 54079, Table B.18. Neurology
(continued) in the first column titled
‘‘Indicator’’,
a. Third and fourth rows, we
inadvertently omitted the substantive
change symbol.
b. Third row, the measure title and
description are inconsistent with the
finalized substantive change, which is
described in Table E.12.
On page 54082, for Table B.18.
Neurology (continued), we
inadvertently included duplicate entries
for Quality #286.
On page 54086, Table B.19. Mental/
Behavioral Health (continued) in the
first column titled ‘‘Indicator’’,
a. Third row, we inadvertently
omitted the substantive change symbol.
b. Third row, the measure title and
description are inconsistent with the
finalized substantive change, which is
described in Table E.12.
On page 54089, Table B.19. Mental/
Behavioral Health (continued) in the
fourth column titled ‘‘CMS E-Measure
ID’’, fourth row, we inadvertently listed
an incorrect E-measure ID.
On page 54091, Table B.19. Mental/
Behavioral Health (continued), we
inadvertently included duplicate entries
for Quality #286.
On page 54094, Table B.20a.
Diagnostic Radiology (continued) in the
first column titled ‘‘Indicator’’, first row,
we inadvertently omitted the high
priority symbol.
On page 54098, Table B.20b.
Interventional Radiology (continued) in
the first column titled ‘‘Indicator’’, fifth
PO 00000
Frm 00011
Fmt 4700
Sfmt 4700
23585
row, we inadvertently omitted the high
priority symbol.
On page 54099, Table B.20b.
Interventional Radiology (continued) in
the first column titled ‘‘Indicator’’,
second row, we inadvertently omitted
the high priority symbol.
On page 54102, Table B.21.
Nephrology (continued) in the first
column titled ‘‘Indicator’’, second row,
we inadvertently omitted the high
priority symbol.
On page 54103, Table B.21.
Nephrology (continued) in the first
column titled ‘‘Indicator’’,
a. First and third rows, we
inadvertently omitted the high priority
symbol.
b. Second row, we inadvertently
omitted the CORE measure symbol.
On page 54109, Table B.23. Vascular
Surgery (continued) in the first column
titled ‘‘Indicator’’, third row, we
inadvertently omitted the high priority
and CORE measure symbols.
On page 54112, Table B.23. Vascular
Surgery (continued) in the first column
titled ‘‘Indicator’’, third row, we
inadvertently omitted the high priority
symbol.
On page 54113, Table B.23. Vascular
Surgery (continued) in the third column
titled ‘‘Quality#’’, first row, due to a
typographical error, the Quality# for the
measure title and description was
incorrect.
On page 54116, Table B.24. Thoracic
Surgery (continued) in the first column
titled ‘‘Indicator’’, fourth row, we
inadvertently omitted the high priority
and CORE measure symbols.
On page 54118, Table B.24. Thoracic
Surgery (continued) in the first column
titled ‘‘Indicator’’, first row, we
inadvertently omitted the high priority
and CORE measure symbols.
On page 54121, Table B.25. Urology
(continued) in the first column titled
‘‘Indicator’’, first row, we inadvertently
omitted the high priority symbol.
On page 54122, Table B.25. Urology
(continued) in the first column titled
‘‘Indicator’’, fifth row, we inadvertently
omitted the high priority symbol.
On page 54123, Table B.25. Urology
(continued) in the first column titled
‘‘Indicator’’,
a. First, second, and third rows, we
inadvertently omitted the high priority
symbol.
On page 54124, Table B.26. Oncology
in the first column titled ‘‘Indicator’’,
third row, we inadvertently omitted the
high priority symbol.
On page 54130, Table B.27.
Hospitalists (continued) in the first
column titled ‘‘Indicator’’, first row, we
inadvertently omitted the high priority
symbol.
E:\FR\FM\22MYR1.SGM
22MYR1
amozie on DSK3GDR082PROD with RULES
23586
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
On page 54134, Table B.28.
Rheumatology (continued) in the first
column titled ‘‘Indicator’’, second row,
we inadvertently omitted the high
priority symbol.
On page 54136, Table B.29. Infectious
Disease (continued) in the first column
titled ‘‘Indicator’’, second row, we
inadvertently omitted the high priority
symbol.
On page 54137, Table B.29. Infectious
Disease (continued) in the first column
titled ‘‘Indicator’’, second row, we
inadvertently omitted the CORE
measure symbol.
On page 54138, Table B.29. Infectious
Disease (continued) in the first column
titled ‘‘Indicator’’, fifth row, we
inadvertently omitted the high priority
and CORE measure symbols.
On page 54139, Table B.29. Infectious
Disease (continued) in the first column
titled ‘‘Indicator’’, first row, we
inadvertently omitted the high priority
symbol.
On page 54141, Table B.30.
Neurosurgical (continued) in the first
column titled ‘‘Indicator’’, third row, we
inadvertently omitted the high priority
symbol.
On page 54142, Table B.30.
Neurosurgical (continued) in the first
column titled ‘‘Indicator’’,
a. Fourth and fifth rows, we
inadvertently omitted the high priority
symbol.
On page 54145, Table B.31. Podiatry
(continued) in the first column titled
‘‘Indicator’’, first row, we inadvertently
omitted the CORE measure symbol.
On page 54146, Table B.32. Dentistry
(continued) in the first column titled
‘‘Indicator’’, first row, we inadvertently
omitted the high priority symbol.
On page 54163, Table E.1. CAHPS for
MIPS Clinician/Group Survey
a. First row titled ‘‘NQF#’’, due to a
typographical error, we included an
incorrect NQF#.
b. Seventh row titled ‘‘Substantive
Change’’, we inadvertently omitted the
SSMs that remain for the measure.
c. Eighth row titled ‘‘Steward’’, we
inadvertently omitted the Centers for
Medicare & Medicaid Services (CMS) as
a co-steward.
On page 54204, in Table G:
Improvement Activities with Changes
for the Quality Payment Program Year 2
and Future Years,
a. Eighteenth row, titled ‘‘Response’’,
we inadvertently added qualifier
language that was incorrect.
b. Nineteenth row, titled ‘‘Rationale’’
we inadvertently added qualifier
language that was incorrect.
On page 54216, in Table G:
Improvement Activities with Changes
for the Quality Payment Program Year 2
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
and Future Years, thirty-ninth row,
titled ‘‘Currently Eligible for Advancing
Care Information Bonus’’, we incorrectly
stated that this activity was not eligible
for the Advancing Care Information
Bonus. IA_PM_13 is eligible for the
Advancing Care Information Bonus.
III. Waiver of Proposed Rulemaking,
60-Day Comment Period, and Delay in
Effective Date
Under 5 U.S.C. 553(b) of the
Administrative Procedure Act (APA),
the agency is required to publish a
notice of the proposed rule in the
Federal Register before the provisions
of a rule take effect. Similarly, section
1871(b)(1) of the Act requires the
Secretary to provide for notice of the
proposed rule in the Federal Register
and provide a period of not less than 60
days for public comment. In addition,
section 553(d) of the APA, and section
1871(e)(1)(B)(i) of the Act mandate a 30day delay in effective date after issuance
or publication of a rule. Sections
553(b)(B) and 553(d)(3) of the APA
provide for exceptions from the notice
and comment and delay in effective date
APA requirements; in cases in which
these exceptions apply, sections
1871(b)(2)(C) and 1871(e)(1)(B)(ii) of the
Act provide exceptions from the notice
and 60-day comment period and delay
in effective date requirements of the Act
as well. Section 553(b)(B) of the APA
and section 1871(b)(2)(C) of the Act
authorize an agency to dispense with
normal rulemaking requirements for
good cause if the agency makes a
finding that the notice and comment
process are impracticable, unnecessary,
or contrary to the public interest. In
addition, both section 553(d)(3) of the
APA and section 1871(e)(1)(B)(ii) of the
Act allow the agency to avoid the 30day delay in effective date where such
delay is contrary to the public interest
and an agency includes a statement of
support.
We believe that this correcting
document does not constitute a rule that
would be subject to the notice and
comment or delayed effective date
requirements. The document corrects
technical errors in the CY 2018 Quality
Payment Program final rule, but does
not make substantive changes to the
policies or payment methodologies that
were adopted in the final rule. As a
result, this correcting document is
intended to ensure that the information
in the CY 2018 Quality Payment
Program final rule accurately reflects the
policies adopted in that document.
In addition, even if this were a rule to
which the notice and comment
procedures and delayed effective date
requirements applied, we find that there
PO 00000
Frm 00012
Fmt 4700
Sfmt 4700
is good cause to waive such
requirements. Undertaking further
notice and comment procedures to
incorporate the corrections in this
document into the final rule or delaying
the effective date would be contrary to
the public interest because it is in the
public’s interest for providers to receive
appropriate payments in as timely a
manner as possible, and to ensure that
the CY 2018 Quality Payment Program
final rule accurately reflects our
methodologies and policies.
Furthermore, such procedures would be
unnecessary, as we are not making
substantive changes to our
methodologies or policies, but rather,
we are simply implementing correctly
the methodologies and policies that we
previously proposed, requested
comment on, and subsequently
finalized. This correcting document is
intended solely to ensure that the CY
2018 Quality Payment Program final
rule accurately reflects these
methodologies and policies. Therefore,
we believe we have good cause to waive
the notice and comment and effective
date requirements.
IV. Correction of Errors
In FR Doc. 2017–24067 (82 FR 53568),
make the following corrections:
A. Correction of Errors in Preamble
1. On page 53577, second column,
second full paragraph, line 10, the
phrase ‘‘of approximately $13.9 million
relative’’ is corrected to read ‘‘of
approximately $14.2 million relative’’.
2. On page 53743, second column,
first full paragraph, under the heading
‘‘(iii) Additional Requirement for Full
Participation To Measure Improvement
for Quality Performance Category’’, line
7, the reference ‘‘§ 414.1330’’ is
corrected to read ‘‘§ 414.1335’’.
3. On page 53744, third column, third
full paragraph, line 6, the reference
‘‘§ 414.1330’’ is corrected to read
‘‘§ 414.1335’’.
4. On page 53900, second column,
first partial paragraph, line 7, the phrase
‘‘burden cost of approximately $13.9’’ is
corrected to read ‘‘burden cost of
approximately $14.2’’.
5. On page 53911, third column,
second full paragraph, line 3, the phrase
‘‘approximately $695 million’’ is
corrected to read ‘‘approximately $694
million’’.
6. On page 53925, first column,
second full paragraph, line 6, the phrase
‘‘total labor cost of $694,183,802’’ is
corrected to read ‘‘total labor cost of
‘‘$693,949,289’’.
7. On page 53925, third column, first
full paragraph, line 3, the phrase ‘‘by
171,264 hours and $13.9 million in’’ is
E:\FR\FM\22MYR1.SGM
22MYR1
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
23587
column, Costs/benefits second row, the
dollar value ‘‘$13.9 million’’ is corrected
to read ‘‘$14.2 million’’.
‘‘costs of $13.9 million in the Quality’’
is corrected to read ‘‘costs of $14.2
million in the Quality’’.
11. On page 53950, first column, first
full paragraph, line 4, the phrase ‘‘will
result in approximately $695’’ is
corrected to read ‘‘will result in
approximately $694’’.
12. On page 53950, second column,
first partial paragraph, line 2, the phrase
‘‘period is and approximately $13.9’’ is
corrected to read ‘‘period is and
approximately $14.2’’.
13. On page 53950, Table 81,
Additional Costs And Benefits second
2. On page 53970, in Table A.4. Bone
Density Evaluation for Patients with
Prostate Cancer and Receiving
Androgen Deprivation Therapy, the
listed entry is corrected to read as
follows:
3. On page 53971, in Table A.5,
Prevention of Post-Operative Vomiting
(POV)—Combination Therapy
(Pediatrics) the listed entry is corrected
to read as follows:
B. Correction of Errors in Appendix
1. On page 53969, in Table A.3.
Average Change in Leg Pain following
Lumbar Discectomy/Laminotomy, the
listed entry is corrected to read as
follows:
ER22MY18.001</GPH>
BILLING CODE 4120–01–P
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00013
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.000</GPH>
amozie on DSK3GDR082PROD with RULES
corrected to read ‘‘by 171,264 hours and
$14.2 million in’’.
8. On page 53925, in Table 74—
Annual Recordkeeping And Submission
Requirements, sixth column, row 2, the
total annual burden cost for QCDR and
Registries self-nomination ‘‘439,786’’ is
corrected to read ‘‘205,273’’.
9. On page 53925, in Table 74—
Annual Recordkeeping And Submission
Requirements, sixth column, row 19, the
total annual burden cost ‘‘694,183,802’’
is corrected to read ‘‘693,949,289’’.
10. On page 53927, first column, first
partial paragraph, line 4, the phrase
23588
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
Arteries, the listed entry is corrected to
read as follows:
listed entries are corrected to read as
follows:
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00014
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.002</GPH>
ER22MY18.003</GPH>
Documentation of Angiographic
Endpoints and Interrogation of Ovarian
5. On pages 53976, 53977 and 53978,
in Table B.1 Allergy/Immunology, the
amozie on DSK3GDR082PROD with RULES
4. On page 53973, in Table A.7,
Uterine Artery Embolization Technique:
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
listed entries are corrected to read as
follows:
PO 00000
Frm 00015
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.004</GPH>
amozie on DSK3GDR082PROD with RULES
6. On pages 53985, 53986, and 53987,
in Table B.3 Cardiology (continued), the
23589
23590
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
ER22MY18.006</GPH>
8. On page 53997, in Table B.5
Dermatology (continued), the listed
entries are corrected to read as follows:
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00016
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.005</GPH>
amozie on DSK3GDR082PROD with RULES
7. On page 53992, in Table B.4
Gastroenterology (continued), the listed
entry is corrected to read as follows:
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
Family Medicine (continued) the listed
entries are corrected to read as follows:
PO 00000
Frm 00017
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.007</GPH>
amozie on DSK3GDR082PROD with RULES
9. On page 54006, 54007, 54009,
54010, 54012, and 54013, in Table B.7
23591
23592
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
B.7. Family Medicine (continued)
0062
119
134v6
Registry,
EHR
Process
Effective
Clinical
Care
0419
amozie on DSK3GDR082PROD with RULES
VerDate Sep<11>2014
68v7
Claims,
Registry,
EHR
Process
Patient
Safety
0022
238
156v6
Registry,
EHR
Process
Patient
Safety
0643
*
130
243
N/A
Registry
Process
Communi
cation and
Care
Coordinati
on
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00018
Fmt 4700
Sfmt 4725
Diabetes: Medical Attention for
Nephropathy: The percentage of
patients 18-75 years of age with
diabetes who had a nephropathy
screening test or evidence of
nephropathy during the
measurement
Documentation of Current
Medications in the Medical
Record:
Percentage of visits for patients
aged 18 years and older for which
the eligible professional attests to
documenting a list of current
medications using all immediate
resources available on the date of
the encounter. This list must
include ALL known prescriptions,
over-the-counters, herbals, and
vitamin/mineral!dietary
(nutritional) supplements AND
must contain the medications'
name, dosage, frequency and route
of administration.
Use of High-Risk Medications in
the Elderly:
Percentage of patients 65 years of
age and older who were ordered
high-risk medications. Two rates
are reported.
a. Percentage of patients who were
ordered at least one high-risk
medication.
b. Percentage of patients who were
ordered at least two of the same
-risk medications.
Cardiac Rehabilitation Patient
Referral from an Outpatient
Setting:
Percentage of patients evaluated in
an outpatient setting who within
the previous 12 months have
experienced an acute myocardial
infarction (MI), coronary artery
bypass graft (CABG) surgery, a
percutaneous coronary intervention
(PCI), cardiac valve surgery, or
cardiac transplantation, or who
have chronic stable angina (CSA)
and have not already participated in
an early outpatient cardiac
E:\FR\FM\22MYR1.SGM
22MYR1
National
Committee for
Quality
Assurance
Centers for
Medicare &
Medicaid
Services
National
Committee for
Quality
Assurance
American
College of
Cardiology
Foundation
ER22MY18.008</GPH>
§
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
(continued), the listed entries are
corrected to read as follows:
PO 00000
Frm 00019
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.009</GPH>
amozie on DSK3GDR082PROD with RULES
10. On pages 54023, 54024, and
54027, in Table B.8 Internal Medicine
23593
23594
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
B.S. Internal Medicine (continued)
238
156v6
EHR,
Registry
Process
Patient
Safety
0643
*
0022
243
N/A
Registry
Process
Communi cat
ion and Care
Coordination
0005
321
N/A
CMSapproved
Survey
Vendor
Patient
Engagement/
Experience
Person and
CaregiverCentered
Experience
and
Outcomes
amozie on DSK3GDR082PROD with RULES
§
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00020
Fmt 4700
Sfmt 4725
Use of High-Risk Medications
in the Elderly:
Percentage of patients 65 years
of age and older who were
ordered high-risk medications.
Two rates are reported.
a. Percentage of patients who
were ordered at least one highrisk medication.
b. Percentage of patients who
were ordered at least two of the
medications.
same
Cardiac Rehabilitation Patient
Referral from an Outpatient
Setting:
Percentage of patients evaluated
in an outpatient setting who
within the previous 12 months
have experienced an acute
myocardial infarction (MI),
coronary artery bypass graft
(CABG) surgery, a percutaneous
coronary intervention (PCI),
cardiac valve surgery, or cardiac
transplantation, or who have
chronic stable angina (CSA) and
have not already participated in
an early outpatient cardiac
rehabilitation/secondary
prevention (CR) program for the
qualifying event/diagnosis who
were referred to a CR program.
National
Committee
for Quality
Assurance
CAHPS for MIPS
Clinician/Group Survey:
Summary Survey Measures may
include:
• Getting Timely Care,
Appointments, and Information;
• How well Providers
Communicate;
• Patient's Rating of Provider;
• Access to Specialists;
• Health Promotion and
Education;
• Shared Decision-Making;
• Health Status and Functional
Status;
• Courteous and Helpful Office
Staff;
• Care Coordination;
• Stewardship of Patient
Resources.
Agency for
Healthcare
Research &
Quality
(AHRQ),
Centers for
Medicare &
Medicaid
Services
E:\FR\FM\22MYR1.SGM
22MYR1
American
College of
Cardiology
Foundation
ER22MY18.010</GPH>
*
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
12. On pages 54047 and 54049, in
Table B.11 Orthopedic Surgery
(continued), the listed entries are
corrected to read as follows:
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00021
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
ER22MY18.012</GPH>
Gynecology (continued), the listed
entries are corrected to read as follows:
22MYR1
ER22MY18.011</GPH>
amozie on DSK3GDR082PROD with RULES
11. On pages 54036, 54037, and
54038, in Table B.9 Obstetrics/
23595
23596
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00022
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.013</GPH>
amozie on DSK3GDR082PROD with RULES
13. On page 54079, in Table B.18
Neurology (continued), the listed entries
are corrected to read as follows:
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
15. On page 54086, 54089, and 54091,
in Table B.19 Mental/Behavioral Health
PO 00000
Frm 00023
Fmt 4700
Sfmt 4700
(continued), the listed entries are
corrected to read as follows:
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.014</GPH>
amozie on DSK3GDR082PROD with RULES
14. On page 54082, in Table B.18
Neurology (continued), the third row
(including the Quality #286) is removed.
23597
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
amozie on DSK3GDR082PROD with RULES
16. On page 54091, in Table B.19
Mental/Behavioral Health (continued),
the third row (including the Quality
#286) is removed.
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
17. On page 54094, in Table B.20a
Diagnostic Radiology (continued), the
listed entry is corrected to read as
follows:
PO 00000
Frm 00024
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.015</GPH>
23598
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
listed entries are corrected to read as
follows:
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00025
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.016</GPH>
ER22MY18.017</GPH>
the listed entries are corrected to read as
follows:
19. On pages 54102 and 54103, in
Table B.21 Nephrology (continued), the
amozie on DSK3GDR082PROD with RULES
18. On page 54098 and 54099, in
Table B.20b Interventional Radiology,
23599
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
amozie on DSK3GDR082PROD with RULES
20. On pages 54109, 54112, and
54113, in Table B.23 Vascular Surgery
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
(continued), the listed entries are
corrected to read as follows:
PO 00000
Frm 00026
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.018</GPH>
23600
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
(continued), the listed entries are
corrected to read as follows:
PO 00000
Frm 00027
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.019</GPH>
amozie on DSK3GDR082PROD with RULES
21. On pages 54116 and 54118, in
Table B.24 Thoracic Surgery
23601
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
amozie on DSK3GDR082PROD with RULES
22. On page 54121, 54122, and 54123,
in Table B.25 Urology (continued), the
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
listed entries are corrected to read as
follows:
PO 00000
Frm 00028
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.020</GPH>
23602
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
23603
B.25. Urology (continued)
0419
130
Claims,
Registry,
68v7
Process
Patient
Safety
EHR
N/A
429
N/A
Claims,
Registry
Process
Patient
Safety
N/A
432
N/A
Registry
Outcome
Patient
Safety
N/A
433
N/A
Registry
Outcome
Patient
Safety
N/A
434
N/A
Registry
Outcome
Patient
Safety
Documentation of Current
Medications in the Medical Record:
Percentage of visits for patients aged
18 years and older for which the
eligible professional attests to
documenting a list of current
medications using all immediate
resources available on the date of the
encounter. This list must include ALL
known prescriptions, over-thecounters, herbals, and
vitamin/mineraVdietary (nutritional)
supplements AND must contain the
medications' name, dosage,
frequency and route of
administration.
Pelvic Organ Prolapse:
Preoperative Screening for Uterine
Malignancy:
Percentage of patients who are
screened for uterine malignancy prior
to vaginal closure or obliterative
for
Proportion of Patients Sustaining a
Bladder Injury at the Time of any
Pelvic Organ Prolapse Repair:
Percentage of patients undergoing
any surgery to repair pelvic organ
prolapse who sustains an injury to the
bladder recognized either during or
within 1 month after
Proportion of Patients Sustaining a
Bowel Injury at the time of any
Pelvic Organ Prolapse Repair:
Percentage of patients undergoing
surgical repair of pelvic organ
prolapse that is complicated by a
bowel injury at the time of index
surgery that is recognized
intraoperatively or within 1 month
after
Proportion of Patients Sustaining a
Ureter Injury at the Time of any
Pelvic Organ Prolapse Repair:
Percentage of patients undergoing
pelvic organ prolapse repairs who
sustain an injury to the ureter
recognized either during or within 1
month after
Centers for
Medicare&
Medicaid
Services
American
Urogynecologi
c Society
American
Urogynecologi
c Society
American
Urogynecologi
c Society
American
Urogynecologi
c Society
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00029
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.021</GPH>
amozie on DSK3GDR082PROD with RULES
23. On page 54124, in Table B.26
Oncology, the listed entry is corrected to
read as follows:
23604
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
24. On page 54130, in Table B.27
Hospitalists (continued), the listed entry
is corrected to read as follows:
ER22MY18.023</GPH>
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00030
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.022</GPH>
amozie on DSK3GDR082PROD with RULES
25. On page 54134, Table B.28
Rheumatology (continued), the listed
entry is corrected to read as follows:
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
Disease (continued), the listed entries
are corrected to read as follows:
PO 00000
Frm 00031
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.024</GPH>
amozie on DSK3GDR082PROD with RULES
26. On pages 54136, 54137, 54138,
and 54139, in Table B.29. Infectious
23605
23606
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
B.29. Infectious Disease (continued)
0419
§
§
130
68v7
Claims,
Registry,
EHR
Process
Patient
Safety
N/A
275
N/A
Registry
Process
Effective
Clinical
Care
2079
390
N/A
Registry
N/A
Registry
Process
Process
Person
and
CaregiverCentered
Experienc
e and
Outcomes
HIV Medical Visit Frequency:
Percentage of patients, regardless of age
with a diagnosis ofHIV who had at
least one medical visit in each 6 month
period of the 24 month measurement
period, with a minimum of 60 days
between medical visits
Hepatitis C: Discussion and Shared
Decision Making Surrounding
Treatment Options:
Percentage of patients aged 18 years and
older with a diagnosis of hepatitis C
with whom a physician or other
qualified healthcare professional
reviewed the range of treatment options
appropriate to their genotype and
demonstrated a shared decision making
approach with the patient. To meet the
measure, there must be documentation
in the patient record of a discussion
between the physician or other qualified
healthcare professional and the patient
that includes all of the following:
treatment choices appropriate to
genotype, risks and benefits, evidence
of effectiveness, and patient preferences
toward treatment
Centers for
Medicare &
Medicaid
Services
American
GastroAssociation
Health
Resources
and Services
Administrati
on
American
Gastroentero
logical
Association
27. On pages 54141 and 54142, in
Table B.30 Neurosurgical, the listed
entries are corrected to read as follows:
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00032
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.025</GPH>
amozie on DSK3GDR082PROD with RULES
N/A
340
Efficiency
and Cost
Reduction
Documentation of Current
Medications in the Medical Record:
Percentage of visits for patients aged 18
years and older for which the eligible
professional attests to documenting a
list of current medications using all
immediate resources available on the
date of the encounter. This list must
include ALL known prescriptions, overthe-counters, herbals, and
vitamin/mineraVdietary (nutritional)
supplements AND must contain the
medications' name, dosage, frequency
and route of administration.
Inflammatory Bowel Disease (IBD):
Assessment of Hepatitis B Virus
(HBV) Status Before Initiating AntiTNF (Tumor Necrosis Factor)
Therapy: Percentage of patients aged
18 years and older with a diagnosis of
inflammatory bowel disease (IBD) who
had Hepatitis B Virus (HBV) status
assessed and results interpreted within
one year prior to receiving a first course
of anti-TNF (tumor necrosis factor)
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
23607
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00033
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.026</GPH>
amozie on DSK3GDR082PROD with RULES
28. On page 54145, in Table B.31
Podiatry (continued), the listed entry is
corrected to read as follows:
23608
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
29. On page 54146, in Table B.32
Dentistry, the listed entry is corrected to
read as follows:
ER22MY18.028</GPH>
Survey, the listed entries are corrected
to read as follows:
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00034
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.027</GPH>
amozie on DSK3GDR082PROD with RULES
30. On page 54163, in Table E.1,
CAHPS for MIPS Clinician/Group
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
and Future Years, the following entries
are corrected to read as follows:
facilities, Health professions, Diseases,
Medicare, Reporting and recordkeeping
requirements.
List of Subjects in 42 CFR Part 414
Accordingly, 42 CFR chapter IV is
corrected by making the following
correcting amendments:
Administrative practice and
procedure, Biologics, Drugs, Health
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
PO 00000
Frm 00035
Fmt 4700
Sfmt 4700
E:\FR\FM\22MYR1.SGM
22MYR1
ER22MY18.029</GPH>
BILLING CODE 4120–01–C
ER22MY18.030</GPH> ER22MY18.031</GPH>
and Future Years, the following entries
are corrected to read as follows:
32. On page 54216, in Table G
Improvement Activities with Changes
for the Quality Payment Program Year 2
amozie on DSK3GDR082PROD with RULES
31. On page 54204, in Table G
Improvement Activities with Changes
for the Quality Payment Program Year 2
23609
23610
Federal Register / Vol. 83, No. 99 / Tuesday, May 22, 2018 / Rules and Regulations
PART 414—PAYMENT FOR PART B
MEDICAL AND OTHER HEALTH
SERVICES
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
1. The authority citation for part 414
continues to read as follows:
■
Authority: Secs. 1102, 1871, and 1881(b)(l)
of the Social Security Act (42 U.S.C. 1302,
1395hh, and 1395rr(b)(l)).
2. Section 414.1370 is amended by
revising paragraphs (g)(1)(ii)(B) and
(h)(5)(i)(B) to read as follows:
■
§ 414.1370
MIPS.
[Amended]
3. Section 414.1380 is amended in
paragraph (b)(1)(xvi)(F) by removing the
reference ‘‘§§ 414.1330’’ and adding in
its place the reference ‘‘§§ 414.1335’’.
■ 4. Section 414.1420 is amended by
revising paragraph (d)(3)(i) to read as
follows:
■
Other payer advanced APM
amozie on DSK3GDR082PROD with RULES
*
*
*
*
*
(d) * * *
(3) * * *
(i) For the 2019 and 2020 QP
Performance Periods, 8 percent of the
total combined revenues from the payer
to providers and other entities under the
payment arrangement if financial risk is
expressly defined in terms of revenue;
or, 3 percent of the expected
expenditures for which an APM Entity
is responsible under the payment
arrangement; or
*
*
*
*
*
Dated: May 16. 2018.
Ann C. Agnew,
Executive Secretary to the Department,
Department of Health and Human Services.
[FR Doc. 2018–10923 Filed 5–21–18; 8:45 am]
BILLING CODE 4120–01–P
VerDate Sep<11>2014
15:59 May 21, 2018
Jkt 244001
Federal Emergency
Management Agency, DHS.
ACTION: Final rule.
AGENCY:
APM scoring standard under
*
*
*
*
(g) * * *
(1) * * *
(ii) * * *
(B) Quality Improvement Score.
Beginning in 2018, for an APM Entity
for which CMS calculated a total quality
performance category score for the
previous MIPS performance period,
CMS calculates a quality improvement
score for the APM Entity group, as
specified in § 414.1380(b)(1)(xvi).
*
*
*
*
*
(h) * * *
(5) * * *
(i) * * *
(B) Beginning in 2018, the advancing
care information performance category
is reweighted to 75 percent and the
improvement activities performance
category is reweighted to 25 percent.
*
*
*
*
*
§ 414.1420
criteria.
[Docket ID FEMA–2018–0002; Internal
Agency Docket No. FEMA–8531]
Suspension of Community Eligibility
*
§ 414.1380
44 CFR Part 64
This rule identifies
communities where the sale of flood
insurance has been authorized under
the National Flood Insurance Program
(NFIP) that are scheduled for
suspension on the effective dates listed
within this rule because of
noncompliance with the floodplain
management requirements of the
program. If the Federal Emergency
Management Agency (FEMA) receives
documentation that the community has
adopted the required floodplain
management measures prior to the
effective suspension date given in this
rule, the suspension will not occur and
a notice of this will be provided by
publication in the Federal Register on a
subsequent date. Also, information
identifying the current participation
status of a community can be obtained
from FEMA’s Community Status Book
(CSB). The CSB is available at https://
www.fema.gov/national-floodinsurance-program-community-statusbook.
SUMMARY:
The effective date of each
community’s scheduled suspension is
the third date (‘‘Susp.’’) listed in the
third column of the following tables.
FOR FURTHER INFORMATION CONTACT: If
you want to determine whether a
particular community was suspended
on the suspension date or for further
information, contact Adrienne L.
Sheldon, PE, CFM, Federal Insurance
and Mitigation Administration, Federal
Emergency Management Agency, 400 C
Street SW, Washington, DC 20472, (202)
212–3966.
SUPPLEMENTARY INFORMATION: The NFIP
enables property owners to purchase
Federal flood insurance that is not
otherwise generally available from
private insurers. In return, communities
agree to adopt and administer local
floodplain management measures aimed
at protecting lives and new construction
from future flooding. Section 1315 of
the National Flood Insurance Act of
1968, as amended, 42 U.S.C. 4022,
prohibits the sale of NFIP flood
DATES:
PO 00000
Frm 00036
Fmt 4700
Sfmt 4700
insurance unless an appropriate public
body adopts adequate floodplain
management measures with effective
enforcement measures. The
communities listed in this document no
longer meet that statutory requirement
for compliance with program
regulations, 44 CFR part 59.
Accordingly, the communities will be
suspended on the effective date in the
third column. As of that date, flood
insurance will no longer be available in
the community. We recognize that some
of these communities may adopt and
submit the required documentation of
legally enforceable floodplain
management measures after this rule is
published but prior to the actual
suspension date. These communities
will not be suspended and will continue
to be eligible for the sale of NFIP flood
insurance. A notice withdrawing the
suspension of such communities will be
published in the Federal Register.
In addition, FEMA publishes a Flood
Insurance Rate Map (FIRM) that
identifies the Special Flood Hazard
Areas (SFHAs) in these communities.
The date of the FIRM, if one has been
published, is indicated in the fourth
column of the table. No direct Federal
financial assistance (except assistance
pursuant to the Robert T. Stafford
Disaster Relief and Emergency
Assistance Act not in connection with a
flood) may be provided for construction
or acquisition of buildings in identified
SFHAs for communities not
participating in the NFIP and identified
for more than a year on FEMA’s initial
FIRM for the community as having
flood-prone areas (section 202(a) of the
Flood Disaster Protection Act of 1973,
42 U.S.C. 4106(a), as amended). This
prohibition against certain types of
Federal assistance becomes effective for
the communities listed on the date
shown in the last column. The
Administrator finds that notice and
public comment procedures under 5
U.S.C. 553(b), are impracticable and
unnecessary because communities listed
in this final rule have been adequately
notified.
Each community receives 6-month,
90-day, and 30-day notification letters
addressed to the Chief Executive Officer
stating that the community will be
suspended unless the required
floodplain management measures are
met prior to the effective suspension
date. Since these notifications were
made, this final rule may take effect
within less than 30 days.
National Environmental Policy Act.
FEMA has determined that the
community suspension(s) included in
this rule is a non-discretionary action
and therefore the National
E:\FR\FM\22MYR1.SGM
22MYR1
]]>Agencies
[Federal Register Volume 83, Number 99 (Tuesday, May 22, 2018)]
[Rules and Regulations]
[Pages 23584-23610]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-10923]
[[Page 23584]]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Part 414
[CMS-5522-F2]
RIN 0938-AT13
Medicare Program; CY 2018 Updates to the Quality Payment Program;
and Quality Payment Program: Extreme and Uncontrollable Circumstance
Policy for the Transition Year; Corrections
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Final rule with comment period and interim final rule with
comment period; correction and correcting amendment.
-----------------------------------------------------------------------
SUMMARY: This document corrects technical errors that appeared in the
final rule with comment period and interim final rule with comment
period published in the Federal Register on November 16, 2017 entitled
``Medicare Program; CY 2018 Updates to the Quality Payment Program; and
Quality Payment Program: Extreme and Uncontrollable Circumstance Policy
for the Transition Year'' (hereinafter referred to as the ``CY 2018
Quality Payment Program final rule'').
DATES: This correction is effective May 22, 2018.
FOR FURTHER INFORMATION CONTACT:
Molly MacHarris, (410) 786-4461, for inquiries related to MIPS.
Benjamin Chin, (410) 786-0679, for inquiries related to APMs.
SUPPLEMENTARY INFORMATION:
I. Background
In FR Doc. 2017-24067 (82 FR 53568), the final rule with comment
period and interim final rule with comment period there were a number
of technical errors that are identified and corrected in the Correction
of Errors section of this correcting document. The provisions in this
correction document are effective as if they had been included in the
document published in the Federal Register on November 16, 2017.
Accordingly, the corrections are applicable for program years beginning
January 1, 2018.
II. Summary of Errors
A. Summary of Errors in Preamble
On page 53577, we inadvertently made an error in citing the
incremental collection of information-related burden.
On page 53743, we inadvertently made an error in identifying the
regulation text citation.
On page 53744, we inadvertently made an error in identifying the
regulation text citation.
On page 53900, we inadvertently made an error in citing the
reduction in burden cost relative to a baseline of continuing the
policies in the CY 2017 Quality Payment Program final rule.
On page 53911, we inadvertently made an error in citing the
estimated data submission burden for the Quality Payment Program.
On page 53925, we inadvertently made an error in citing the total
estimated labor cost for annual recordkeeping and data submission.
On page 53925, we inadvertently made an error in citing the
decrease in labor cost burden relative to the estimated baseline of
continued transition year policies.
On page 53925, Table 74--Annual Recordkeeping And Submission
Requirements
a. Sixth column titled ``Total annual burden cost'', second row, we
inadvertently made an error in citing the total annual burden cost for
QCDR and Registries self-nomination.
b. Sixth column titled ``Total annual burden cost'', nineteenth
row, we inadvertently made an error in citing the total annual burden
cost.
On page 53927, we inadvertently made an error in citing the
reduction in burden costs in the Quality Payment Program Year 2
relative to Quality Payment Program Year 1.
On page 53950, we inadvertently made an error in citing the
collection of information-related burden associated with the CY 2018
Quality Payment Program final rule with comment period.
On page 53950, we inadvertently made an error in citing the
reduction in incremental collection of information-related burden
associated with the CY 2018 Quality Payment Program final rule with
comment period relative to the baseline burden of continuing the
policies and information collections set forth in the CY 2017 Quality
Program final rule.
On page 53950, Table 81--Additional Costs And Benefits, in the
second column titled ``Costs/benefits'', second row, we inadvertently
made an error in citing the incremental collection of information/
Paperwork Reduction Act burden estimates.
B. Summary of Errors in Regulation Text
On page 53954, in the regulation text at Sec.
414.1370(g)(1)(ii)(B), we inadvertently made errors in identifying the
beginning CY performance period for which CMS calculates a quality
improvement score for an APM Entity.
On page 53954, at 414.1370(h)(5)(i)(B), due to typographical
errors, the percent values for the advancing care information
performance category and the improvement activities performance
category are incorrect.
On page 53957, we inadvertently made an error in identifying the
regulation text citation.
On page 53961, at Sec. 414.1420(d)(3)(i), we inadvertently deleted
the existing regulation text regarding the expected expenditures
standard.
C. Summary of Errors in Appendix
On page 53969, Table A.3. Average Change in Leg Pain following
Lumbar Discectomy/Laminotomy, Quality #461, we inadvertently omitted
the MAP recommendation description in the ``Rationale''.
On page 53970, Table A.4. Bone Density Evaluation for Patients with
Prostate Cancer and Receiving Androgen Deprivation Therapy, Quality
#462, we incorrectly identified the MAP recommendation description in
the ``Rationale''.
On page 53971, Table A.5. Prevention of Post-Operative Vomiting
(POV)--Combination Therapy (Pediatrics), Quality #463 we inadvertently
omitted the MAP recommendation description in the ``Rationale''.
On page 53973, Table A.7. Uterine Artery Embolization Technique:
Documentation of Angiographic Endpoints and Interrogation of Ovarian
Arteries, Quality #465, we inadvertently omitted the MAP recommendation
description in the ``Rationale''.
On page 53976, Table B.1. Allergy/Immunology in the first column
titled ``Indicator'', third row, we inadvertently omitted the high
priority symbol.
On page 53977, Table B.1. Allergy/Immunology (continued) in the
first column titled ``Indicator'', second row, we inadvertently omitted
the high priority symbol.
On page 53978, Table B.1. Allergy/Immunology (continued) in the
first column titled ``Indicator'', third row, we inadvertently omitted
the CORE measure and the high priority symbols.
On page 53985, Table B.3. Cardiology (continued) in the first
column titled ``Indicator'',
a. Third row, we inadvertently omitted the CORE measure and the
high priority symbols.
b. Fourth row, we inadvertently omitted the high priority symbol.
On page 53986, Table B.3. Cardiology (continued) in the first
column titled
[[Page 23585]]
``Indicator'', first row, we inadvertently omitted the high priority
symbol.
On page 53987, Table B.3. Cardiology (continued) in the first
column titled ``Indicator'', fifth row, we inadvertently omitted the
high priority symbol.
On page 53992, Table B.4. Gastroenterology (continued) in the first
column titled ``Indicator'', third row, we inadvertently omitted the
CORE measure symbol.
On page 53997, Table B.5. Dermatology (continued),
a. First column titled ``Indicator'', third row, we inadvertently
omitted the high priority symbol.
b. Fifth column titled ``Data Submission Method'', second row, we
inadvertently listed an incorrect claims submission method.
On page 54006, Table B.7. Family Medicine (continued) in the fourth
column titled ``CMS E-measure ID'', fifth row, we inadvertently listed
an incorrect E-measure ID.
On page 54007, Table B.7. Family Medicine (continued) in the first
column titled ``Indicator'', second row, we inadvertently omitted the
high priority symbol.
On page 54009, Table B.7. Family Medicine (continued) in the first
column titled ``Indicator'', first and second rows, we inadvertently
omitted the high priority symbol.
On page 54010, Table B.7. Family Medicine (continued),
a. Second column titled ``NQF#'', third row, due to a typographical
error, we included an incorrect NQF#.
b. Ninth column titled ``Measure Steward'', third row, we
inadvertently omitted the Centers for Medicare & Medicaid Services
(CMS) as a co-steward.
On page 54012, Table B.7. Family Medicine (continued) in the first
column titled ``Indicator'', fifth row, we inadvertently omitted the
high priority symbol.
On page 54013, Table B.7. Family Medicine (continued) in the first
column titled ``Indicator'', first row, we inadvertently omitted the
high priority symbol.
On page 54023, Table B.8. Internal Medicine (continued), in the
first column titled ``Indicator'', First and second rows, we
inadvertently omitted the high priority symbol.
On pages 54024, Table B.8. Internal Medicine (continued),
a. Second column titled ``NQF#'', third row, due to a typographical
error, we included an incorrect NQF#.
b. Ninth column titled ``Measure Steward'', third row, we
inadvertently omitted the Centers for Medicare & Medicaid Services
(CMS) as a co-steward.
On page 54027, Table B.8. Internal Medicine (continued), in the
first column titled ``Indicator'', third and fifth rows, we
inadvertently omitted the high priority symbol.
On page 54036, Table B.9. Obstetrics/Gynecology (continued), in the
first column titled ``Indicator'', sixth row, we inadvertently omitted
the high priority symbol.
On page 54037, Table B.9. Obstetrics/Gynecology (continued), in the
first column titled ``Indicator'', second and fourth rows, we
inadvertently omitted the high priority symbol.
On page 54038, Table B.9. Obstetrics/Gynecology (continued), ninth
column, fourth row, we inadvertently listed an incorrect measure
steward.
On page 54047, Table B.11. Orthopedic Surgery (continued) in the
first column titled ``Indicator'', fifth row, we inadvertently omitted
the high priority symbol.
On page 54049, Table B.11. Orthopedic Surgery (continued) in the
first column titled ``Indicator'', third row, we inadvertently omitted
the substantive change symbol.
On page 54079, Table B.18. Neurology (continued) in the first
column titled ``Indicator'',
a. Third and fourth rows, we inadvertently omitted the substantive
change symbol.
b. Third row, the measure title and description are inconsistent
with the finalized substantive change, which is described in Table
E.12.
On page 54082, for Table B.18. Neurology (continued), we
inadvertently included duplicate entries for Quality #286.
On page 54086, Table B.19. Mental/Behavioral Health (continued) in
the first column titled ``Indicator'',
a. Third row, we inadvertently omitted the substantive change
symbol.
b. Third row, the measure title and description are inconsistent
with the finalized substantive change, which is described in Table
E.12.
On page 54089, Table B.19. Mental/Behavioral Health (continued) in
the fourth column titled ``CMS E-Measure ID'', fourth row, we
inadvertently listed an incorrect E-measure ID.
On page 54091, Table B.19. Mental/Behavioral Health (continued), we
inadvertently included duplicate entries for Quality #286.
On page 54094, Table B.20a. Diagnostic Radiology (continued) in the
first column titled ``Indicator'', first row, we inadvertently omitted
the high priority symbol.
On page 54098, Table B.20b. Interventional Radiology (continued) in
the first column titled ``Indicator'', fifth row, we inadvertently
omitted the high priority symbol.
On page 54099, Table B.20b. Interventional Radiology (continued) in
the first column titled ``Indicator'', second row, we inadvertently
omitted the high priority symbol.
On page 54102, Table B.21. Nephrology (continued) in the first
column titled ``Indicator'', second row, we inadvertently omitted the
high priority symbol.
On page 54103, Table B.21. Nephrology (continued) in the first
column titled ``Indicator'',
a. First and third rows, we inadvertently omitted the high priority
symbol.
b. Second row, we inadvertently omitted the CORE measure symbol.
On page 54109, Table B.23. Vascular Surgery (continued) in the
first column titled ``Indicator'', third row, we inadvertently omitted
the high priority and CORE measure symbols.
On page 54112, Table B.23. Vascular Surgery (continued) in the
first column titled ``Indicator'', third row, we inadvertently omitted
the high priority symbol.
On page 54113, Table B.23. Vascular Surgery (continued) in the
third column titled ``Quality#'', first row, due to a typographical
error, the Quality# for the measure title and description was
incorrect.
On page 54116, Table B.24. Thoracic Surgery (continued) in the
first column titled ``Indicator'', fourth row, we inadvertently omitted
the high priority and CORE measure symbols.
On page 54118, Table B.24. Thoracic Surgery (continued) in the
first column titled ``Indicator'', first row, we inadvertently omitted
the high priority and CORE measure symbols.
On page 54121, Table B.25. Urology (continued) in the first column
titled ``Indicator'', first row, we inadvertently omitted the high
priority symbol.
On page 54122, Table B.25. Urology (continued) in the first column
titled ``Indicator'', fifth row, we inadvertently omitted the high
priority symbol.
On page 54123, Table B.25. Urology (continued) in the first column
titled ``Indicator'',
a. First, second, and third rows, we inadvertently omitted the high
priority symbol.
On page 54124, Table B.26. Oncology in the first column titled
``Indicator'', third row, we inadvertently omitted the high priority
symbol.
On page 54130, Table B.27. Hospitalists (continued) in the first
column titled ``Indicator'', first row, we inadvertently omitted the
high priority symbol.
[[Page 23586]]
On page 54134, Table B.28. Rheumatology (continued) in the first
column titled ``Indicator'', second row, we inadvertently omitted the
high priority symbol.
On page 54136, Table B.29. Infectious Disease (continued) in the
first column titled ``Indicator'', second row, we inadvertently omitted
the high priority symbol.
On page 54137, Table B.29. Infectious Disease (continued) in the
first column titled ``Indicator'', second row, we inadvertently omitted
the CORE measure symbol.
On page 54138, Table B.29. Infectious Disease (continued) in the
first column titled ``Indicator'', fifth row, we inadvertently omitted
the high priority and CORE measure symbols.
On page 54139, Table B.29. Infectious Disease (continued) in the
first column titled ``Indicator'', first row, we inadvertently omitted
the high priority symbol.
On page 54141, Table B.30. Neurosurgical (continued) in the first
column titled ``Indicator'', third row, we inadvertently omitted the
high priority symbol.
On page 54142, Table B.30. Neurosurgical (continued) in the first
column titled ``Indicator'',
a. Fourth and fifth rows, we inadvertently omitted the high
priority symbol.
On page 54145, Table B.31. Podiatry (continued) in the first column
titled ``Indicator'', first row, we inadvertently omitted the CORE
measure symbol.
On page 54146, Table B.32. Dentistry (continued) in the first
column titled ``Indicator'', first row, we inadvertently omitted the
high priority symbol.
On page 54163, Table E.1. CAHPS for MIPS Clinician/Group Survey
a. First row titled ``NQF#'', due to a typographical error, we
included an incorrect NQF#.
b. Seventh row titled ``Substantive Change'', we inadvertently
omitted the SSMs that remain for the measure.
c. Eighth row titled ``Steward'', we inadvertently omitted the
Centers for Medicare & Medicaid Services (CMS) as a co-steward.
On page 54204, in Table G: Improvement Activities with Changes for
the Quality Payment Program Year 2 and Future Years,
a. Eighteenth row, titled ``Response'', we inadvertently added
qualifier language that was incorrect.
b. Nineteenth row, titled ``Rationale'' we inadvertently added
qualifier language that was incorrect.
On page 54216, in Table G: Improvement Activities with Changes for
the Quality Payment Program Year 2 and Future Years, thirty-ninth row,
titled ``Currently Eligible for Advancing Care Information Bonus'', we
incorrectly stated that this activity was not eligible for the
Advancing Care Information Bonus. IA_PM_13 is eligible for the
Advancing Care Information Bonus.
III. Waiver of Proposed Rulemaking, 60-Day Comment Period, and Delay in
Effective Date
Under 5 U.S.C. 553(b) of the Administrative Procedure Act (APA),
the agency is required to publish a notice of the proposed rule in the
Federal Register before the provisions of a rule take effect.
Similarly, section 1871(b)(1) of the Act requires the Secretary to
provide for notice of the proposed rule in the Federal Register and
provide a period of not less than 60 days for public comment. In
addition, section 553(d) of the APA, and section 1871(e)(1)(B)(i) of
the Act mandate a 30-day delay in effective date after issuance or
publication of a rule. Sections 553(b)(B) and 553(d)(3) of the APA
provide for exceptions from the notice and comment and delay in
effective date APA requirements; in cases in which these exceptions
apply, sections 1871(b)(2)(C) and 1871(e)(1)(B)(ii) of the Act provide
exceptions from the notice and 60-day comment period and delay in
effective date requirements of the Act as well. Section 553(b)(B) of
the APA and section 1871(b)(2)(C) of the Act authorize an agency to
dispense with normal rulemaking requirements for good cause if the
agency makes a finding that the notice and comment process are
impracticable, unnecessary, or contrary to the public interest. In
addition, both section 553(d)(3) of the APA and section
1871(e)(1)(B)(ii) of the Act allow the agency to avoid the 30-day delay
in effective date where such delay is contrary to the public interest
and an agency includes a statement of support.
We believe that this correcting document does not constitute a rule
that would be subject to the notice and comment or delayed effective
date requirements. The document corrects technical errors in the CY
2018 Quality Payment Program final rule, but does not make substantive
changes to the policies or payment methodologies that were adopted in
the final rule. As a result, this correcting document is intended to
ensure that the information in the CY 2018 Quality Payment Program
final rule accurately reflects the policies adopted in that document.
In addition, even if this were a rule to which the notice and
comment procedures and delayed effective date requirements applied, we
find that there is good cause to waive such requirements. Undertaking
further notice and comment procedures to incorporate the corrections in
this document into the final rule or delaying the effective date would
be contrary to the public interest because it is in the public's
interest for providers to receive appropriate payments in as timely a
manner as possible, and to ensure that the CY 2018 Quality Payment
Program final rule accurately reflects our methodologies and policies.
Furthermore, such procedures would be unnecessary, as we are not making
substantive changes to our methodologies or policies, but rather, we
are simply implementing correctly the methodologies and policies that
we previously proposed, requested comment on, and subsequently
finalized. This correcting document is intended solely to ensure that
the CY 2018 Quality Payment Program final rule accurately reflects
these methodologies and policies. Therefore, we believe we have good
cause to waive the notice and comment and effective date requirements.
IV. Correction of Errors
In FR Doc. 2017-24067 (82 FR 53568), make the following
corrections:
A. Correction of Errors in Preamble
1. On page 53577, second column, second full paragraph, line 10,
the phrase ``of approximately $13.9 million relative'' is corrected to
read ``of approximately $14.2 million relative''.
2. On page 53743, second column, first full paragraph, under the
heading ``(iii) Additional Requirement for Full Participation To
Measure Improvement for Quality Performance Category'', line 7, the
reference ``Sec. 414.1330'' is corrected to read ``Sec. 414.1335''.
3. On page 53744, third column, third full paragraph, line 6, the
reference ``Sec. 414.1330'' is corrected to read ``Sec. 414.1335''.
4. On page 53900, second column, first partial paragraph, line 7,
the phrase ``burden cost of approximately $13.9'' is corrected to read
``burden cost of approximately $14.2''.
5. On page 53911, third column, second full paragraph, line 3, the
phrase ``approximately $695 million'' is corrected to read
``approximately $694 million''.
6. On page 53925, first column, second full paragraph, line 6, the
phrase ``total labor cost of $694,183,802'' is corrected to read
``total labor cost of ``$693,949,289''.
7. On page 53925, third column, first full paragraph, line 3, the
phrase ``by 171,264 hours and $13.9 million in'' is
[[Page 23587]]
corrected to read ``by 171,264 hours and $14.2 million in''.
8. On page 53925, in Table 74--Annual Recordkeeping And Submission
Requirements, sixth column, row 2, the total annual burden cost for
QCDR and Registries self-nomination ``439,786'' is corrected to read
``205,273''.
9. On page 53925, in Table 74--Annual Recordkeeping And Submission
Requirements, sixth column, row 19, the total annual burden cost
``694,183,802'' is corrected to read ``693,949,289''.
10. On page 53927, first column, first partial paragraph, line 4,
the phrase ``costs of $13.9 million in the Quality'' is corrected to
read ``costs of $14.2 million in the Quality''.
11. On page 53950, first column, first full paragraph, line 4, the
phrase ``will result in approximately $695'' is corrected to read
``will result in approximately $694''.
12. On page 53950, second column, first partial paragraph, line 2,
the phrase ``period is and approximately $13.9'' is corrected to read
``period is and approximately $14.2''.
13. On page 53950, Table 81, Additional Costs And Benefits second
column, Costs/benefits second row, the dollar value ``$13.9 million''
is corrected to read ``$14.2 million''.
B. Correction of Errors in Appendix
1. On page 53969, in Table A.3. Average Change in Leg Pain
following Lumbar Discectomy/Laminotomy, the listed entry is corrected
to read as follows:
BILLING CODE 4120-01-P
[GRAPHIC] [TIFF OMITTED] TR22MY18.000
2. On page 53970, in Table A.4. Bone Density Evaluation for
Patients with Prostate Cancer and Receiving Androgen Deprivation
Therapy, the listed entry is corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.001
3. On page 53971, in Table A.5, Prevention of Post-Operative
Vomiting (POV)--Combination Therapy (Pediatrics) the listed entry is
corrected to read as follows:
[[Page 23588]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.002
4. On page 53973, in Table A.7, Uterine Artery Embolization
Technique: Documentation of Angiographic Endpoints and Interrogation of
Ovarian Arteries, the listed entry is corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.003
5. On pages 53976, 53977 and 53978, in Table B.1 Allergy/
Immunology, the listed entries are corrected to read as follows:
[[Page 23589]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.004
6. On pages 53985, 53986, and 53987, in Table B.3 Cardiology
(continued), the listed entries are corrected to read as follows:
[[Page 23590]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.005
7. On page 53992, in Table B.4 Gastroenterology (continued), the
listed entry is corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.006
8. On page 53997, in Table B.5 Dermatology (continued), the listed
entries are corrected to read as follows:
[[Page 23591]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.007
9. On page 54006, 54007, 54009, 54010, 54012, and 54013, in Table
B.7 Family Medicine (continued) the listed entries are corrected to
read as follows:
[[Page 23592]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.008
[[Page 23593]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.009
10. On pages 54023, 54024, and 54027, in Table B.8 Internal
Medicine (continued), the listed entries are corrected to read as
follows:
[[Page 23594]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.010
[[Page 23595]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.011
11. On pages 54036, 54037, and 54038, in Table B.9 Obstetrics/
Gynecology (continued), the listed entries are corrected to read as
follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.012
12. On pages 54047 and 54049, in Table B.11 Orthopedic Surgery
(continued), the listed entries are corrected to read as follows:
[[Page 23596]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.013
13. On page 54079, in Table B.18 Neurology (continued), the listed
entries are corrected to read as follows:
[[Page 23597]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.014
14. On page 54082, in Table B.18 Neurology (continued), the third
row (including the Quality #286) is removed.
15. On page 54086, 54089, and 54091, in Table B.19 Mental/
Behavioral Health (continued), the listed entries are corrected to read
as follows:
[[Page 23598]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.015
16. On page 54091, in Table B.19 Mental/Behavioral Health
(continued), the third row (including the Quality #286) is removed.
17. On page 54094, in Table B.20a Diagnostic Radiology (continued),
the listed entry is corrected to read as follows:
[[Page 23599]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.016
18. On page 54098 and 54099, in Table B.20b Interventional
Radiology, the listed entries are corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.017
19. On pages 54102 and 54103, in Table B.21 Nephrology (continued),
the listed entries are corrected to read as follows:
[[Page 23600]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.018
20. On pages 54109, 54112, and 54113, in Table B.23 Vascular
Surgery (continued), the listed entries are corrected to read as
follows:
[[Page 23601]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.019
21. On pages 54116 and 54118, in Table B.24 Thoracic Surgery
(continued), the listed entries are corrected to read as follows:
[[Page 23602]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.020
22. On page 54121, 54122, and 54123, in Table B.25 Urology
(continued), the listed entries are corrected to read as follows:
[[Page 23603]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.021
23. On page 54124, in Table B.26 Oncology, the listed entry is
corrected to read as follows:
[[Page 23604]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.022
24. On page 54130, in Table B.27 Hospitalists (continued), the
listed entry is corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.023
25. On page 54134, Table B.28 Rheumatology (continued), the listed
entry is corrected to read as follows:
[[Page 23605]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.024
26. On pages 54136, 54137, 54138, and 54139, in Table B.29.
Infectious Disease (continued), the listed entries are corrected to
read as follows:
[[Page 23606]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.025
27. On pages 54141 and 54142, in Table B.30 Neurosurgical, the
listed entries are corrected to read as follows:
[[Page 23607]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.026
28. On page 54145, in Table B.31 Podiatry (continued), the listed
entry is corrected to read as follows:
[[Page 23608]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.027
29. On page 54146, in Table B.32 Dentistry, the listed entry is
corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.028
30. On page 54163, in Table E.1, CAHPS for MIPS Clinician/Group
Survey, the listed entries are corrected to read as follows:
[[Page 23609]]
[GRAPHIC] [TIFF OMITTED] TR22MY18.029
31. On page 54204, in Table G Improvement Activities with Changes
for the Quality Payment Program Year 2 and Future Years, the following
entries are corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.030
32. On page 54216, in Table G Improvement Activities with Changes
for the Quality Payment Program Year 2 and Future Years, the following
entries are corrected to read as follows:
[GRAPHIC] [TIFF OMITTED] TR22MY18.031
BILLING CODE 4120-01-C
List of Subjects in 42 CFR Part 414
Administrative practice and procedure, Biologics, Drugs, Health
facilities, Health professions, Diseases, Medicare, Reporting and
recordkeeping requirements.
Accordingly, 42 CFR chapter IV is corrected by making the following
correcting amendments:
[[Page 23610]]
PART 414--PAYMENT FOR PART B MEDICAL AND OTHER HEALTH SERVICES
0
1. The authority citation for part 414 continues to read as follows:
Authority: Secs. 1102, 1871, and 1881(b)(l) of the Social
Security Act (42 U.S.C. 1302, 1395hh, and 1395rr(b)(l)).
0
2. Section 414.1370 is amended by revising paragraphs (g)(1)(ii)(B) and
(h)(5)(i)(B) to read as follows:
Sec. 414.1370 APM scoring standard under MIPS.
* * * * *
(g) * * *
(1) * * *
(ii) * * *
(B) Quality Improvement Score. Beginning in 2018, for an APM Entity
for which CMS calculated a total quality performance category score for
the previous MIPS performance period, CMS calculates a quality
improvement score for the APM Entity group, as specified in Sec.
414.1380(b)(1)(xvi).
* * * * *
(h) * * *
(5) * * *
(i) * * *
(B) Beginning in 2018, the advancing care information performance
category is reweighted to 75 percent and the improvement activities
performance category is reweighted to 25 percent.
* * * * *
Sec. 414.1380 [Amended]
0
3. Section 414.1380 is amended in paragraph (b)(1)(xvi)(F) by removing
the reference ``Sec. Sec. 414.1330'' and adding in its place the
reference ``Sec. Sec. 414.1335''.
0
4. Section 414.1420 is amended by revising paragraph (d)(3)(i) to read
as follows:
Sec. 414.1420 Other payer advanced APM criteria.
* * * * *
(d) * * *
(3) * * *
(i) For the 2019 and 2020 QP Performance Periods, 8 percent of the
total combined revenues from the payer to providers and other entities
under the payment arrangement if financial risk is expressly defined in
terms of revenue; or, 3 percent of the expected expenditures for which
an APM Entity is responsible under the payment arrangement; or
* * * * *
Dated: May 16. 2018.
Ann C. Agnew,
Executive Secretary to the Department, Department of Health and Human
Services.
[FR Doc. 2018-10923 Filed 5-21-18; 8:45 am]
BILLING CODE 4120-01-P
